
Pandion Therapeutics, Inc. Long-Term Debt 2011-2026 | PAND
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Pandion Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | 3.68 M | 2.01 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.68 M | 2.01 M | 2.84 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
130 K | $ 0.89 | - | $ 6.54 M | ||
|
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
42 M | $ 22.2 | - | $ 3.68 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | ||
|
Edesa Biotech
EDSA
|
19.8 K | $ 15.9 | - | $ 50.8 M | ||
|
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | ||
|
Exelixis
EXEL
|
173 M | $ 44.69 | - | $ 12.1 B | ||
|
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | ||
|
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - | ||
|
Grifols, S.A.
GRFS
|
5.9 B | $ 7.91 | - | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
144 M | $ 31.05 | - | $ 1.79 B | ||
|
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
7.49 M | $ 8.44 | - | $ 76.2 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
171 K | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
231 M | $ 101.57 | - | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | ||
|
Immuron Limited
IMRN
|
175 K | $ 0.81 | 0.3 % | $ 9.47 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | ||
|
Incyte Corporation
INCY
|
30.2 M | $ 99.1 | - | $ 19.3 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
InMed Pharmaceuticals
INM
|
16 K | $ 0.7 | - | $ 1.71 M | ||
|
INmune Bio
INMB
|
411 K | $ 1.33 | - | $ 32.9 M | ||
|
Innoviva
INVA
|
258 M | $ 23.05 | - | $ 1.55 B | ||
|
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
16.9 M | $ 1.48 | -0.67 % | $ 235 M | ||
|
Jaguar Health
JAGX
|
892 K | $ 7.88 | - | $ 18.4 M | ||
|
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
38.2 M | - | - | $ 28.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
172 M | $ 26.67 | - | $ 1.44 B | ||
|
AlloVir
ALVR
|
1.13 M | - | 4.14 % | $ 49.1 M | ||
|
Kamada Ltd.
KMDA
|
36 K | $ 8.11 | - | $ 260 M | ||
|
Krystal Biotech
KRYS
|
7.57 M | $ 259.95 | - | $ 7.52 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
49 K | $ 224.86 | - | $ 4.11 B | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | ||
|
Liquidia Corporation
LQDA
|
19.9 M | $ 38.15 | - | $ 3.28 B | ||
|
Applied Therapeutics
APLT
|
38 K | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
45 M | $ 4.05 | - | $ 433 M | ||
|
Aptinyx
APTX
|
22.1 M | - | -39.0 % | $ 4.57 M |